Avia Pharma acquires Neubourg, a German market leader within foam-based footcare
STOCKHOLM, Sweden, 2 February 2024 – Avia Pharma Holding AB (“Avia” or the “Company”) has completed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care. Through the acquisition, Avia adds a strong dermatology brand portfolio in Germany to its platform, including, Allpresan, the German market […]
Avia Pharma welcomes Impilo as a new partner
STOCKHOLM, Sweden, 2 February 2024 – During January, Avia Pharma Holding AB (“Avia” or the “Company”), welcomed Impilo AB as a new owner and partner to the co-founders. Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies. The partnership with Impilo will allow Avia to execute on its strategy and ambition […]
ACO Vitamin D acquisition
Avia Pharma has today completed the acquisition of ACO Vitamin D water and will as the new marketing authorisation holder re-launch the pharmaceutical in the Swedish market in Q4 this year. “The acquisition allows us to continue offering this complement to D-vitamin oil”, says Marie Wikman, Business Unit Director Avia Pharma. For further information, please […]
Nyvigan launch in Swedish pharmacies
Avia Pharma is launching Nyvigan in Swedish pharmacies. Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida. Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the intercrural-region and the perianal region. […]
Avia Parma makes its third acquisition in 2022
Avia Pharma has today completed the acquisition of Unimedic’s Vitamin D oil. “The acquisition is in line with Avia Pharma’s strategy to own more products and will complement our existing portfolio”, says Jacob Calmvik, CEO of Avia Pharma. For further information, please contact Jacob Calmvik, CEO Avia Pharma, jacob.calmvik@aviapharma.se, +46 703 70 71 69
Avia Pharma expands into Germany
Avia Pharma has today completed the acquisition of Allergika Pharma GmbH. The company has a turnover of close to 15 million EUR and is placed in Wolfratshausen, near Munich. Allergika is a German pharmaceutical company focused on the allergy market. It sells both dermatology products and encasing under its own brands. The dermatology products have, […]
Avia Pharma acquires Decem Pharma
Avia Pharma has today completed the acquisition of Decem Pharma. Decem Pharma is a Finish pharmaceutical company with its own brands with strong market positions, such as Magnecit and Otocur. The acquisition of Decem Pharma is Avia Pharma’s first acquisition outside of Sweden and part of its strategy to build a northern European pharmaceutical company. […]
More products added to the cooperation between Perrigo and Avia Pharma
Following a strong sales increase in the current portfolio, Avia Pharma and Perrigo have deepened the relationship to also include Vectavir®, Vectatone®, Oralmedic® and Predictor®.
Avia Pharma appoints Mattias Wik as Business Unit Director Women’s Health
Avia Pharma appoints Mattias Wik as Business Unit Director Oncology/Urology.
